Pharmacodynamic Endpoints as Clinical Trial Objectives to Answer Important Questions in Oncology Drug Development

Seminars in Oncology - United Kingdom
doi 10.1053/j.seminoncol.2016.07.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The 150 Most Important Questions in Cancer Research and Clinical Oncology Series: Questions 6–14

Chinese Journal of Cancer
2017English

The Most Important Questions in Cancer Research and Clinical Oncology—Question 2–5. Obesity-Related Cancers: More Questions Than Answers

Chinese Journal of Cancer
2017English

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies

Oncologist
Cancer ResearchMedicineOncology
2017English

Biomarkers in Oncology Drug Development

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2008English

Regulatory Considerations on Endpoints in Ovarian Cancer Drug Development

Cancer
Cancer ResearchOncology
2017English

Bridging Adult Experience to Pediatrics in Oncology Drug Development

Journal of Clinical Pharmacology
Pharmacology
2017English

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”

Oncologist
Cancer ResearchMedicineOncology
2017English

Very Short Answer Questions: The Answer to the Perfect Medical Assessment? [Letter]

Advances in Medical Education and Practice
2019English

Radiation Oncology Clinical Trial Design: An Opportunity to Evaluate Value

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy